Results 11 to 20 of about 15,263 (254)
Cicatricial ectropion in a patient treated with dupilumab
American Journal of Ophthalmology Case Reports, 2017 Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two ...
Julian Perry, Alexander D Blandford
exaly +4 more sources
Clinical and Translational Allergy, 2023 Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten
exaly +2 more sources
MMR and varicella immunization during dupilumab therapy [PDF]
Journal of Allergy and Clinical Immunology: GlobalBackground: The US Food and Drug Administration recommends deferring administration of live vaccines during dupilumab treatment owing to lack of data on safety and efficacy.
Hannah Seay, MD +6 more
doaj +2 more sources
Conjunctivitis in patients with atopic dermatitis treated with dupilumab [PDF]
Drugs in Context, 2020 Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL- 13 are key cytokines in the immunopathogenesis of AD.
Sandra Ferreira, Tiago Torres
doaj +2 more sources
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
American Journal of Ophthalmology Case Reports, 2020 Purpose: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. Observations: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy.
Meghan Berkenstock +2 more
exaly +3 more sources
Dupilumab – a novel treatment option against allergic diseases: a state-of-the-art review
Alergologia PolskaDupilumab is a humanized, IgG4 monoclonal antibody which binds to the α subunit of interleukin 4 receptor (IL-4R) and interleukin 13 receptor (IL-13R), thereby it inhibits their action.
Klaudia Kołakowska, Maciej Czubek
doaj +2 more sources
How Can Dupilumab Cause Eosinophilic Pneumonia?
Biomolecules, 2022 Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are limited in previous studies. Herein, we report two cases in which EP developed subsequent to the administration of dupilumab for eosinophilic chronic rhinosinusitis ...
Momoko Kurihara +14 more
doaj +2 more sources
New‐Onset Vitiligo During Dupilumab Treatment: A Clinical Observation and Literature Review [PDF]
The Clinical Respiratory JournalIntroduction Vitiligo is a rare adverse event associated with dupilumab. This study aims to describe a case of new‐onset vitiligo following dupilumab treatment in a Chinese patient and to systematically review the literature to characterize its clinical ...
Xuhui Pu, Suzhen Ju, Yanfang Yu
doaj +2 more sources
Clinical & Experimental Allergy, 2019 AbstractThe Th2 cytokines interleukin 4 (IL‐4) and IL‐13 and the heterodimeric IL‐4 receptor (IL‐4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL‐4 receptor alpha chain (IL‐4Rα), common to both IL‐4R complexes: type 1 (IL‐4Rα/γc; IL‐4 ...
Hani Harb, Talal A. Chatila
openaire +2 more sources
Dupilumab-associated cicatrizing ocular disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be ...
Amit K. Reddy +4 more
doaj +1 more source